Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Oct 1, 2019
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding a skin condition called hidradenitis suppurativa (HS), which causes painful bumps and can greatly affect a person's quality of life. The study aims to gather detailed information about the symptoms and biological characteristics of HS to help create a better classification system and identify potential new treatments. Researchers are currently looking for participants of all genders, aged 10 years and older, who have been diagnosed with HS by a qualified medical professional.
If you or a loved one decides to join this study, you'll be asked to provide written consent and may need to complete some questionnaires and follow-ups. This research is important because it will help us learn more about HS, which is often misunderstood, and could lead to improved care for those living with this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female ≥ 10 years of age
- • 2. Diagnosis of HS by a dermatologist or practitioner experienced in making a diagnosis of HS
- • 3. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
- Exclusion Criteria:
- • 1. Inability to give informed consent or unavailability of a parent/guardian who is able and willing to give informed consent.
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Haley B Naik, MD, MHSc, FAAD
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials